Espoo, Finland - Mendor, a leading diabetes technology company, is pleased to
announce it has completed a new series of growth financing for further global
expansion totaling € 6,5 Million. The financing came from Luxembourg based IPF
Partners.
Mendor is a fast growing diabetes technology company, committed to the design,
development and commercialization of next generation diabetes care products.
Mendor’s vision is a future where diabetes care is integrated, individual and
outcome driven.
Mendor’s two main products are:
Mendor Discreet® – a unique all-in-one blood glucose monitoring system, which
contains all the necessary components for daily blood glucose measurements: a
meter, 25 strips and a lancing device in an integrated, stylish device the size
of a mobile phone.
Mendor Balance® – a cloud-based diabetes data analytics and care platform for
storing, sharing and analyzing individual glucose data from more than 30
different glucose meters, for the improvement of diabetes care.
IPF Partners is a leading alternative financing provider focused on the European
healthcare sector. IPF I, the first fund managed by IPF, invests directly in
emerging, commercial-stage European pharma/biotech, medtech and diagnostics
companies. The company was founded in 2011 by a seasoned multi-disciplinary team
combining over 50 years of finance and investment and over 30 years of
healthcare experience. IPF has developed a unique business model using the
team's specialist sector knowledge to provide bespoke, long-term financing
solutions. Following its first closing in October 2013, the fund has €80 million
of assets under management.
For more information, visit: www.mendor.com / www.ipfpartners.com